Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediates reduced pulmonary inflammation in mice

References

1. Anderson L. J., Bingham P., Hierholzer J. C. 1988; Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol 62:4232–4238
   [Google Scholar]
2. Brown B. A., Comeau R. D., Jones P. L., Liberatore F. A., Neacy W. P., Sands H., Gallagher B. M. 1987; Pharmokinetics of the monoclonal antibody B72.3 and its fragments labeled with either ¹²⁵I or ¹¹¹In. Cancer Res 47:1149–1154
   [Google Scholar]
3. Corbeil S., Seguin C., Trudel M. 1996; Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2. Vaccine 14:521–525 [CrossRef]
   [Google Scholar]
4. Falsey A. R., Cunningham C. K., Barker W. H., Kouides R. W., Yuen J. B., Menegus M., Weiner L. B., Bonville C. A., Betts R. F. 1995; Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 172:389–394 [CrossRef]
   [Google Scholar]
5. Fodha I., Vabret A., Bouslama L., Leroux M., Legrand L., Dina J., Gouarin S., Petitjean J., Dewar J. other authors 2008; Molecular diversity of the aminoterminal region of the G protein gene of human respiratory syncytial virus subgroup B. Pathol Biol (Paris) 56:50–57 [CrossRef]
   [Google Scholar]
6. Hall C. B., Walsh E. E., Long C. E., Schnabel K. C. 1991; Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163:693–698 [CrossRef]
   [Google Scholar]
7. Harcourt J. L., Brown M. P., Anderson L. J., Tripp R. A. 2003; CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice. Vaccine 21:2964–2979 [CrossRef]
   [Google Scholar]
8. Harcourt J. L., Karron R. A., Tripp R. A. 2004; Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C–CX3CR1 binding and leukocyte chemotaxis. J Infect Dis 190:1936–1940 [CrossRef]
   [Google Scholar]
9. Harcourt J. L., Alvarex R., Jones L. P., Henderson C., Anderson L. J., Tripp R. A. 2006; Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1⁺ T cell responses. J Immunol 176:1600–1608 [CrossRef]
   [Google Scholar]
10. Haynes L. M., Tonkin J., Anderson L. J., Tripp R. A. 2002; Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J Virol 76:6873–6881 [CrossRef]
    [Google Scholar]
11. Haynes L. M., Jones L. P., Barskey A., Anderson L. J., Tripp R. A. 2003; Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C–CX3CR1 interaction and expression of substance P. J Virol 77:9831–9844 [CrossRef]
    [Google Scholar]
12. Hirsch R. L. 1982; The complement system: its importance in the host response to viral infection. Microbiol Rev 46:71–85
    [Google Scholar]
13. Mejías A., Chávez-Beuno S., Ríos A. M., Saavedra-Lozano J., Fonseca Aten M., Hatfield J., Kapur P., Gómez A. M., Jafri H. S., Ramilo O. 2004; Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 48:1811–1822 [CrossRef]
    [Google Scholar]
14. Mekseepralard C., Toms G. L., Routledge E. G. 2006; Protection of mice against human respiratory syncytial virus by wild-type and aglycosyl mouse–human chimeric IgG antibodies to subgroup-conserved epitopes on the G glycoprotein. J Gen Virol 87:1267–1273 [CrossRef]
    [Google Scholar]
15. Panitch H. B. 2001; Bronchiolitis in infants. Curr Opin Pediatr 13:256–260 [CrossRef]
    [Google Scholar]
16. Plotnicky-Gilquin H., Goetsch L., Huss T., Champion T., Beck A., Haeuw J., Nguyen T. N., Bonnefoy J., Corvaïa N., Power U. F. 1999; Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J Virol 73:5637–5645
    [Google Scholar]
17. Shay D. K., Holman R. C., Newman R. D., Liu L. L., Stout J. W., Anderson L. J. 1999; Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 282:1440–1446 [CrossRef]
    [Google Scholar]
18. Sullender W. 1995; Antigenic analysis of chimeric and truncated G proteins of respiratory syncytial virus. Virology 209:70–79 [CrossRef]
    [Google Scholar]
19. Tripp R. A. 2004; Pathogenesis of respiratory syncytial virus infection. Viral Immunol 17:165–181 [CrossRef]
    [Google Scholar]
20. Tripp R. A., Moore D., Jones L., Sullender W., Winter J., Anderson L. J. 1999; Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol 73:7099–7107
    [Google Scholar]
21. Tripp R. A., Jones L. P., Haynes L. M., Zheng H., Murphy P. M., Anderson L. J. 2001; CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2:732–738 [CrossRef]
    [Google Scholar]
22. Varga S. M., Brachiale T. J. 2002; RSV-induced immunopathology: dynamic interplay between the virus and host immune response. Virology 295:203–207 [CrossRef]
    [Google Scholar]